Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Mesothelioma, Malignant 2Unspecified Adult Solid Tumor 1Thymoma 1Solid Tumor Cancer 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Endometrial Stromal 1Rhabdomyosarcoma, Embryonal 1Relapsed Pediatric Solid Tumor 1Primary Myelofibrosis 1Pleural Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Multiple Myeloma 1Metastatic Solid Tumors. 1Melanoma 1Mastocytosis 1Malignant mesenchymal tumor 1Liposarcoma 1Leukemia, Mast-Cell 1Leiomyosarcoma 1Hypereosinophilic Syndrome 1Hemangiosarcoma 1Hemangiopericytoma 1Fibroma 1Dermatofibrosarcoma 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Solid Tumors. × Imatinib Mesylate × Other solid neoplasm × Clear all
NCT00159016 2011-04-28

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Hadassah Medical Organization

Phase 2 Withdrawn
100 enrolled
Other solid neoplasm

Metastatic Solid Tumors.

Data powered by HemOnc (CC BY 4.0) Colophon âš¡